Delving into the Latest Updates on Edrophonium Chloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Edrophonium chloride (JP17/USP/INN), Antirex, Enlon

+ [3]

Target

AChE

Mechanism

AChE inhibitors(Acetylcholinesterase inhibitors), Muscle relaxation antagonists

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [1]

Active Indication

Myasthenia GravisReversal of Neuromuscular Blockade

Inactive Indication-

Originator Organization

VJGJ, Inc.

Active Organization

KYORIN Pharmaceutical Co., Ltd.Jinan Boshi Medical Technology Co., Ltd.

Inactive Organization

PAI Holdings LLC

Drug Highest PhaseApproved

First Approval Date

US (03 May 1951),

Myasthenia Gravis

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H16ClNO

InChIKeyBXKDSDJJOVIHMX-UHFFFAOYSA-N

CAS Registry116-38-1

主要目的：研究依酚氯铵注射液在全身麻醉手术后患者中与硫酸阿托品注射液同时单次静脉注射给药的药代动力学特征，并与国外文献数据进行对比分析，为借鉴原研产品说明书的用法用量提供药代动力学依据。次要目的：评估依酚氯铵注射液的安全性；初步评估依酚氯铵注射液拮抗残留神经肌肉阻滞的疗效。

[Translation]

The main purpose is to study the pharmacokinetic characteristics of edrophonium injection administered as a single intravenous injection in patients undergoing general anesthesia surgery and to compare and analyze the data from foreign literature to provide a pharmacokinetic basis for the use and dosage of the original product instructions. The secondary purpose is to evaluate the safety of edrophonium injection and preliminarily evaluate the efficacy of edrophonium injection in antagonizing residual neuromuscular blockade.

Start Date-

Sponsor / Collaborator

Jinan Boshi Medical Technology Co., Ltd.

JPRN-UMIN000022557 / CompletedIIT

Edrophonium challenge test for dystonia - Edrophonium test for dystonia

Start Date01 Jun 2012

Sponsor / Collaborator-

NCT00748059 / CompletedPhase 1IIT

The Pathophysiology of Orthostatic Hypotension

The purpose of this study is to determine the cause of low blood pressure in selective patients who have problems with their involuntary (autonomic) nervous system. These patients frequently have had symptoms throughout their life, and their disorder might have a genetic basis. The biochemical, physiological and pharmacological procedures in this study should help us define the problem and perhaps lead to more effective treatment.

Start Date01 Dec 1996

Sponsor / Collaborator

Vanderbilt University Medical Center

100 Clinical Results associated with Edrophonium Chloride

Login to view more data

100 Translational Medicine associated with Edrophonium Chloride

Login to view more data

100 Patents (Medical) associated with Edrophonium Chloride

Login to view more data

968

Literatures (Medical) associated with Edrophonium Chloride

01 Feb 2024·Current Drug Safety

Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade in Adults and Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Review

Author: Gupta, Lalit K ; Chhabra, Ridhi ; Gupta, Rachna

Background:Cholinesterase inhibitors, such as neostigmine and edrophonium, commonly used to reverse the residual effects of nondepolarizing neuromuscular blocking drugs at the end of surgery are associated with a high rate of residual neuromuscular blockade (NMB). Due to its direct mechanism of action, sugammadex is associated with rapid and predictable reversal of deep NMB. The current analysis compares the clinical efficacy and risk of postoperative nausea and vomiting (PONV) on using sugammadex or neostigmine for routine NMB reversal in adult and pediatric populations.Methods:PubMed and ScienceDirect were searched as the primary databases. Randomized controlled trials comparing sugammadex with neostigmine for routine NMB reversal in adult and pediatric patients have been included. The primary efficacy endpoint was the time from initiation of sugammadex or neostigmine to the recovery of a time-of-four ratio (TOF) ≥ 0.9. PONV events have been reported as secondary outcomes.Results:A total of 26 studies have been included in this meta-analysis, 19 for adults with 1574 patients and 7 for children with 410 patients. Sugammadex, when compared to neostigmine, has been reported to take a shorter time to reverse NMB in adults (mean difference = -14.16 min; 95% CI [-16.88, -11.43], P < 0.01), as well as in children (mean difference = -26.36 min; 95% CI [- 40.16, -12.57], P < 0.01). Events of PONV have been found to be similar in both the groups in adults, but significantly lower in children treated with sugammadex, i.e., 7 out of 145 with sugammadex versus 35 out of 145 with neostigmine (odds ratio = 0.17; 95% CI [0.07, 0.40]).Conclusion:Sugammadex is associated with a significantly shorter period of reversal from NMB in comparison to neostigmine in adult and pediatric patients. Regarding PONV, the use of sugammadex for NMB antagonism may offer a better option for pediatric patients.

01 Jan 2024·Internal Medicine

Unusual Presentation of Double-seronegative Myasthenia Gravis with Positive Anti-LRP4 Antibody: Diagnostic Utility of a Videofluoroscopic Swallowing Study

Article

Author: Higuchi, Osamu ; Ishihara, Shoichiro ; Takahashi, Sunao ; Oniki, Ayako ; Yanai, Kensaku ; Tomimitsu, Hiroyuki ; Soejima, Itsuki ; Matsuda, Toshiya

An 86-year-old woman was admitted to our hospital with cryptogenic progressive dyspnea and dysphagia following a tracheostomy procedure 4 months prior to presentation. She exhibited fluctuating diplopia, bilateral vocal fold paralysis, normal nerve test results, negative findings for serum anti-acetylcholine receptor and anti-muscle-specific kinase antibodies, and positive findings for anti-LDL-receptor related protein 4 (LRP4). A videofluoroscopic swallowing study (VFSS) with edrophonium revealed an improvement in bulbar paralysis. Consequently, the patient was diagnosed with double-seronegative myasthenia gravis (DSN-MG) and began immunomodulatory therapy. This case emphasizes the diagnostic challenges of bulbar-type DSN-MG and underscores the value of a VFSS with edrophonium for diagnosing this condition.

01 Jan 2023·Journal of the Neurological Sciences

Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/−associated antibodies

Letter

Author: Sakamoto, Naohiro ; Takazaki, Hiroshi ; Suzuki, Kazushi ; Yamazaki, Keishi ; Isa, Megumi ; Asakuma, Junichi ; Ikewaki, Katsunori ; Hongo, Yu

In recent years, immune checkpoint inhibitors (ICI) have become the standard treatments for various cancers. These drugs are monoclonal antibodies targeting mols. such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), and PD-1 ligand (PD-L1). ICI activate the immune system to eliminate malignancies.Here, we report a case of myositis/myocarditis with multiple myositis-specific-antibodies (MSAs) and myositis-associated-antibodies (MAAs) during use of pembrolizumab, a PD-1 inhibitor, which improved with immunotherapy.The result of ice pack test was neg. in this case. I.v. administration of edrophonium did not improve ptosis (1-A), grip strength and upper/ lower limb muscle strength. As described above, the various tests to detect myasthenic symptoms were neg.When clinicians encounter neuroimmune disorders during ICI treatment, it is sometimes difficult to determine whether they are drugderived reactions or tumor-associated symptoms.If the symptoms are drug-derived, the ICI should be discontinued, however, if the symptoms are tumor-related, the ICI should be continued. Simultaneous-positivemultiple MSAs is suggestive of an ICI-derived autoimmune response and may be a useful insight for clinicians treating myositis during ICI use to select a more appropriate treatment.

100 Deals associated with Edrophonium Chloride

Login to view more data